Answer
Serious infusion-associated reactions occurred in 3% of patients treated with Lemtrada (alemtuzumab) in multiple sclerosis clinical trials.
Sources for this answer
- LEMTRADA 12 mg concentrate for solution for infusionSANOFI · emc · SmPC §4.4 Special warnings and precautions for use · Version 2Document updated
Sources checked